“…However, when investigated in vivo, using the CYP2C8-dependent substrate, pioglitazone, this inhibitory potential of montelukast was not realized, with negligible impact on the pharmacokinetics of the drug (Jaakkola et al, 2006). There also does not appear to be any inhibitory effects in vivo on CYP1A2, as assessed by theophylline metabolism (Malmstrom et al, 1998), or CYP2C9, as assessed by warfarin metabolism (Van Hecken et al, 1999), at least not at clinical doses of montelukast.…”